## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($85.33)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Wedge Capital Management L L P NC Sells 17,263 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251222T130823 | Neutral | Relevance: 100%
- Wedge Capital Management L.L.P. NC has reduced its stake in Zimmer Biomet Holdings, Inc. by 21.3%, selling 17,263 shares and retaining 63,914 shares valued at approximately $6.296 million. The medical equipment provider recently reported Q3 EPS of $1.90, beating analyst estimates, and announced a quarterly dividend of $0.24. Analysts currently have a consensus "Hold" rating on ZBH stock with a target price of $107.50.

**2. Douglas Lane & Associates LLC Purchases 29,011 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251221T100848 | Neutral | Relevance: 100%
- Douglas Lane & Associates LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.2% in the third quarter, purchasing an additional 29,011 shares. This brings their total holdings to 431,360 shares, valued at approximately $42.49 million. The company currently has a "Hold" rating from analysts with a consensus target price of $107.50, and recently reported Q3 EPS of $1.90, beating estimates.

**3. Benson Investment Management Company Inc. Acquires New Position in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251221T080857 | Somewhat-Bullish | Relevance: 100%
- Benson Investment Management Company Inc. has acquired a new position of 50,430 shares in Zimmer Biomet Holdings, Inc. worth approximately $4.97 million during the third quarter. Institutional investors now own about 88.89% of the medical equipment provider's stock. Zimmer Biomet recently reported strong quarterly earnings and revenue, while setting optimistic FY2025 guidance.

**4. Zimmer Biomet Holdings (NYSE:ZBH) Shareholders Have Endured a 36% Loss From Investing in the Stock Five Years Ago**
- Source: 富途牛牛 | 20251220T150826 | Somewhat-Bearish | Relevance: 100%
- Zimmer Biomet Holdings shareholders have experienced a 36% loss over the last five years, with the stock down 40% in that period, although the total shareholder return (TSR) including dividends is also -36%. Despite transitioning from a loss to profitability and showing a 3.2% revenue increase, the share price has languished. The article suggests that investors should look closer at the fundamentals and consider analyst forecasts to understand the company's future prospects.

**5. Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24**
- Source: Yahoo Finance | 20251220T120844 | Bullish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has announced a dividend of $0.24 per share, resulting in a 1.1% yield. The company's future dividend payments appear well-covered by earnings, with a projected payout ratio of 15% next year. With a solid track record of consistent dividend payments and strong EPS growth, Zimmer Biomet Holdings is considered a promising dividend stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 8.6% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Forward P/E 10.6x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.8B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 10.6 |
| Current P/E | 11.0 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.2% to -4.1% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.1pp (needs >4.0% for momentum thesis). AM_20 at -3.6% indicates price below own 20MA trend. Underperforming sector by 4.0pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 40. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.13% (CS: 12) | Weak |
| RSI_14 | 40.1 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 0.947x | Below |
| vs SMA200 | 0.914x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $89.75
- **Stop Loss:** $85.33 (4.9% risk)
- **Target:** $98.59 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 271
- **Position Value:** $24,322.25
- **Portfolio %:** 24.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*